Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3716606 | 0.82 | GRM2 (0.32) | MAPK1 | |
| SCHEMBL3658952 | 0.80 | NR3C2 (0.37) | MAPK1ALDH1A1POLB | |
| SCHEMBL15331769 | 0.80 | — | — | |
| SCHEMBL31375944 | 0.76 | MPO (0.36) | MAPK1ALDH1A1 | |
| SCHEMBL25382537 | 0.76 | UBE2M (0.34) | MAPK1KDM4EHTR2C | |
| SCHEMBL1648042 | 0.76 | MEN1 (0.36) | MAPK1ALDH1A1POLB | |
| SCHEMBL16548434 | 0.74 | MAPK1 (0.53) | MAPK1ALDH1A1HTR2C | |
| SCHEMBL16815514 | 0.74 | MAPK1 (0.34) | MAPK1ALDH1A1HTR2C | |
| SCHEMBL18250248 | 0.73 | MAPK1 (0.36) | MAPK1ALDH1A1POLBHTR2C | |
| SCHEMBL20197195 | 0.73 | ALDH1A1 (0.33) | MAPK1ALDH1A1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20170135994-A9 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20160184281-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160184282-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-9193723-B2 | NAMPT inhibitors | ABBVIE INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9187472-B2 | NAMPT inhibitors | ABBVIE INC. (US) | 2015-11-17 | — | — | US | disclosed |
| EP-2847192-A1 | NAMPT INHIBITORS | AbbVie Inc. (US) | 2015-03-18 | — | — | EP | disclosed |
| CN-104428301-A | NAMPT inhibitors | ABBVIE INC | 2015-03-18 | — | — | CN | disclosed |
| WO-2013170112-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| US-20130303508-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303511-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303508-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | MAPK1 3544/4885ALDH1A1 1573/4885KDM4E 3407/4885 |
| US-20160184282-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | MAPK1 3544/4885ALDH1A1 1573/4885KDM4E 3407/4885 |
| US-20130303511-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | MAPK1 3544/4885ALDH1A1 1573/4885KDM4E 3407/4885 |
| US-20160184281-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | MAPK1 3544/4885ALDH1A1 1573/4885KDM4E 3407/4885 |
| US-20170135994-A9 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | MAPK1 3544/4885ALDH1A1 1573/4885KDM4E 3407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.